Comparative Efficacy and Safety of Combined Radiotherapy and Adjuvant Hormone Therapy (Leuprorelin SR 11.25 mg) and Hormone Therapy Alone (Leuprorelin SR 11.25 mg) in Locally Advanced Prostate Cancer (T3-T4 or pT3 on Biopsy, N0, M0)
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Sponsors Laboratoires Takeda
Most Recent Events
- 05 Jun 2018 Results assessing long-term oncological outcomes, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 01 Aug 2012 Results published in European Urology.
- 06 Jun 2010 Results presented at ASCO 2010.